KR20160113319A - 칼시토닌의 경구 투여 - Google Patents
칼시토닌의 경구 투여 Download PDFInfo
- Publication number
- KR20160113319A KR20160113319A KR1020167025673A KR20167025673A KR20160113319A KR 20160113319 A KR20160113319 A KR 20160113319A KR 1020167025673 A KR1020167025673 A KR 1020167025673A KR 20167025673 A KR20167025673 A KR 20167025673A KR 20160113319 A KR20160113319 A KR 20160113319A
- Authority
- KR
- South Korea
- Prior art keywords
- calcitonin
- cnac
- oral
- minutes
- sct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title claims abstract description 75
- 102000055006 Calcitonin Human genes 0.000 title claims abstract description 41
- 108060001064 Calcitonin Proteins 0.000 title claims abstract description 41
- 229960004015 calcitonin Drugs 0.000 title claims abstract description 40
- 229940124447 delivery agent Drugs 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 claims description 38
- 235000012054 meals Nutrition 0.000 claims description 26
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 8
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000027868 Paget disease Diseases 0.000 claims description 3
- 230000000148 hypercalcaemia Effects 0.000 claims description 3
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 3
- 208000027202 mammary Paget disease Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 5
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 34
- 108010068072 salmon calcitonin Proteins 0.000 description 34
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 239000003826 tablet Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- XGSDAQOSOKPJML-UHFFFAOYSA-L disodium;8-[(5-chloro-2-oxidobenzoyl)amino]octanoate Chemical compound [Na+].[Na+].[O-]C(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1[O-] XGSDAQOSOKPJML-UHFFFAOYSA-L 0.000 description 12
- 229960000913 crospovidone Drugs 0.000 description 11
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 11
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 159000000000 sodium salts Chemical class 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- -1 Paget's disease Chemical compound 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229940069328 povidone Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 229920003084 Avicel® PH-102 Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- XUHVCHNJCBBXMP-UHFFFAOYSA-M sodium;10-[(2-hydroxybenzoyl)amino]decanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCCCC([O-])=O XUHVCHNJCBBXMP-UHFFFAOYSA-M 0.000 description 3
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CBEKBPBDTOIYKJ-UHFFFAOYSA-N 2-amino-11-(2-hydroxyphenyl)-11-oxoundecanoic acid Chemical compound OC(=O)C(N)CCCCCCCCC(=O)C1=CC=CC=C1O CBEKBPBDTOIYKJ-UHFFFAOYSA-N 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- KSIYPKPZIBBUFR-LJNLPFSOSA-N CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O Chemical compound CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O KSIYPKPZIBBUFR-LJNLPFSOSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010016948 Food interaction Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021158 dinner Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000021156 lunch Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical class O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40013902P | 2002-08-01 | 2002-08-01 | |
| US60/400,139 | 2002-08-01 | ||
| PCT/EP2003/008498 WO2004012772A1 (en) | 2002-08-01 | 2003-07-31 | Oral administration of calcitonin |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147016376A Division KR20140084354A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177022695A Division KR20170097232A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160113319A true KR20160113319A (ko) | 2016-09-28 |
Family
ID=31495795
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167025673A Ceased KR20160113319A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
| KR1020177022695A Ceased KR20170097232A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
| KR1020127031292A Ceased KR20130004389A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
| KR1020147016376A Ceased KR20140084354A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
| KR1020057001733A Ceased KR20050032101A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
| KR1020107029690A Ceased KR20110014690A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177022695A Ceased KR20170097232A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
| KR1020127031292A Ceased KR20130004389A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
| KR1020147016376A Ceased KR20140084354A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
| KR1020057001733A Ceased KR20050032101A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
| KR1020107029690A Ceased KR20110014690A (ko) | 2002-08-01 | 2003-07-31 | 칼시토닌의 경구 투여 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20060135402A1 (enExample) |
| EP (1) | EP1526871A1 (enExample) |
| JP (4) | JP2005535689A (enExample) |
| KR (6) | KR20160113319A (enExample) |
| CN (1) | CN1671418A (enExample) |
| AR (1) | AR040737A1 (enExample) |
| AU (1) | AU2003260346B2 (enExample) |
| BR (1) | BR0313177A (enExample) |
| CA (1) | CA2494212A1 (enExample) |
| IL (1) | IL166337A (enExample) |
| MX (1) | MXPA05001266A (enExample) |
| NO (1) | NO20051023L (enExample) |
| NZ (1) | NZ537944A (enExample) |
| PE (1) | PE20040724A1 (enExample) |
| PL (1) | PL373143A1 (enExample) |
| RU (1) | RU2355417C2 (enExample) |
| TW (1) | TWI307279B (enExample) |
| WO (1) | WO2004012772A1 (enExample) |
| ZA (1) | ZA200500516B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20070548A1 (es) * | 2005-09-19 | 2007-07-12 | Emisphere Tech Inc | Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico |
| GB0522566D0 (en) * | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
| WO2008109385A2 (en) * | 2007-03-02 | 2008-09-12 | Novartis Ag | Oral administration of a calcitonin |
| WO2009019307A2 (en) * | 2007-08-09 | 2009-02-12 | Novartis Ag | Oral calcitonin compositions and applications thereof |
| US8022048B2 (en) | 2007-11-02 | 2011-09-20 | Emisphere Technologies, Inc. | Method of treating vitamin B12 deficiency |
| US20110039930A1 (en) * | 2009-08-03 | 2011-02-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
| WO2012130193A1 (en) | 2011-03-31 | 2012-10-04 | Zentiva, K.S. | Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration |
| CN104095828A (zh) * | 2014-07-29 | 2014-10-15 | 中国药科大学 | 一种降钙素口服肠溶组合物及其制备方法 |
| WO2016128972A1 (en) | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Formulations for oral administration of active agents with controlled absorption profile |
| CN104961687B (zh) * | 2015-06-03 | 2017-07-25 | 苏州维泰生物技术有限公司 | 1,2‑二嗪衍生物及其制剂、用途 |
| MX2019001850A (es) | 2016-08-17 | 2019-05-15 | Entera Bio Ltd | Formulaciones para administracion oral de principios activos. |
| CR20230308A (es) | 2020-12-11 | 2023-09-08 | Civi Biopharma Inc | Entrega oral de conjugados antisentido que tienen por blanco a pcsk9 |
| MX2023012437A (es) | 2021-04-22 | 2023-11-07 | Civi Biopharma Inc | Administracion oral de oligonucleotidos. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| WO2000059480A1 (en) * | 1999-04-05 | 2000-10-12 | Emisphere Technologies, Inc. | Lyophilized solid dosage forms and methods of making |
| NZ534409A (en) * | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
-
2003
- 2003-07-30 AR AR20030102740A patent/AR040737A1/es unknown
- 2003-07-30 PE PE2003000747A patent/PE20040724A1/es not_active Application Discontinuation
- 2003-07-30 TW TW092120855A patent/TWI307279B/zh not_active IP Right Cessation
- 2003-07-31 KR KR1020167025673A patent/KR20160113319A/ko not_active Ceased
- 2003-07-31 JP JP2004525407A patent/JP2005535689A/ja not_active Withdrawn
- 2003-07-31 KR KR1020177022695A patent/KR20170097232A/ko not_active Ceased
- 2003-07-31 RU RU2005105691/15A patent/RU2355417C2/ru not_active IP Right Cessation
- 2003-07-31 US US10/523,421 patent/US20060135402A1/en not_active Abandoned
- 2003-07-31 PL PL03373143A patent/PL373143A1/xx unknown
- 2003-07-31 AU AU2003260346A patent/AU2003260346B2/en not_active Ceased
- 2003-07-31 KR KR1020127031292A patent/KR20130004389A/ko not_active Ceased
- 2003-07-31 KR KR1020147016376A patent/KR20140084354A/ko not_active Ceased
- 2003-07-31 WO PCT/EP2003/008498 patent/WO2004012772A1/en not_active Ceased
- 2003-07-31 BR BR0313177-7A patent/BR0313177A/pt not_active Application Discontinuation
- 2003-07-31 CA CA002494212A patent/CA2494212A1/en not_active Abandoned
- 2003-07-31 NZ NZ537944A patent/NZ537944A/en not_active IP Right Cessation
- 2003-07-31 MX MXPA05001266A patent/MXPA05001266A/es unknown
- 2003-07-31 EP EP03766387A patent/EP1526871A1/en not_active Ceased
- 2003-07-31 CN CNA038182955A patent/CN1671418A/zh active Pending
- 2003-07-31 KR KR1020057001733A patent/KR20050032101A/ko not_active Ceased
- 2003-07-31 KR KR1020107029690A patent/KR20110014690A/ko not_active Ceased
-
2005
- 2005-01-17 IL IL166337A patent/IL166337A/en active IP Right Grant
- 2005-01-19 ZA ZA200500516A patent/ZA200500516B/xx unknown
- 2005-02-25 NO NO20051023A patent/NO20051023L/no unknown
-
2007
- 2007-05-24 US US11/805,748 patent/US7569539B2/en not_active Expired - Fee Related
-
2010
- 2010-11-08 JP JP2010249363A patent/JP2011026348A/ja active Pending
-
2013
- 2013-12-02 JP JP2013249349A patent/JP5941035B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001745A patent/JP2016056190A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016056190A (ja) | 2016-04-21 |
| NO20051023L (no) | 2005-04-27 |
| KR20110014690A (ko) | 2011-02-11 |
| PE20040724A1 (es) | 2004-12-06 |
| TW200408409A (en) | 2004-06-01 |
| IL166337A (en) | 2011-10-31 |
| AR040737A1 (es) | 2005-04-20 |
| AU2003260346A1 (en) | 2004-02-23 |
| KR20170097232A (ko) | 2017-08-25 |
| KR20140084354A (ko) | 2014-07-04 |
| JP5941035B2 (ja) | 2016-06-29 |
| US20070232524A1 (en) | 2007-10-04 |
| WO2004012772A1 (en) | 2004-02-12 |
| AU2003260346B2 (en) | 2007-12-13 |
| NZ537944A (en) | 2006-11-30 |
| BR0313177A (pt) | 2005-06-14 |
| RU2005105691A (ru) | 2006-01-20 |
| US7569539B2 (en) | 2009-08-04 |
| MXPA05001266A (es) | 2005-04-28 |
| CA2494212A1 (en) | 2004-02-12 |
| TWI307279B (en) | 2009-03-11 |
| CN1671418A (zh) | 2005-09-21 |
| JP2011026348A (ja) | 2011-02-10 |
| US20060135402A1 (en) | 2006-06-22 |
| JP2014062112A (ja) | 2014-04-10 |
| KR20050032101A (ko) | 2005-04-06 |
| PL373143A1 (en) | 2005-08-22 |
| EP1526871A1 (en) | 2005-05-04 |
| JP2005535689A (ja) | 2005-11-24 |
| IL166337A0 (en) | 2006-01-16 |
| ZA200500516B (en) | 2006-07-26 |
| KR20130004389A (ko) | 2013-01-09 |
| RU2355417C2 (ru) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7569539B2 (en) | Oral administration of calcitonin | |
| RU2493868C2 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ | |
| CA2679782C (en) | Oral administration of a calcitonin | |
| KR100847695B1 (ko) | 약리학적 활성 약물의 경구적 전달을 위한 약제학적 조성물 | |
| JP2005535689A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20160919 Application number text: 1020147016376 Filing date: 20140616 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20161201 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20170614 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20161201 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20170714 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20170614 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2017101003383 Request date: 20170714 |
|
| J121 | Written withdrawal of request for trial | ||
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20170816 |
|
| PJ1201 | Withdrawal of trial |
Patent event code: PJ12011R01D Patent event date: 20170816 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2017101003383 Request date: 20170714 Appeal kind category: Appeal against decision to decline refusal Decision date: 20170816 |
|
| WITB | Written withdrawal of application |